GERON CORP (GERN)
Sector: Health Care
2026 Annual Meeting Analysis
GERON CORP · Meeting: May 20, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors — Class III Nominees for a Three-Year Term Expiring at the 2029 Annual Meeting
Against Analysis
Dr. Molineaux has served since 2012 and her tenure fully overlaps Geron's severe stock underperformance: over the past three years, Geron's stock fell 21.2% while the company's own disclosed peer group of 23 biotech companies gained a median of 63.4%, a gap of 84.6 percentage points that far exceeds the 20-point threshold required to trigger an AGAINST vote for directors overseeing a stock with negative absolute returns; the five-year record does not provide relief, as Geron's 12.5% five-year gain still trails the peer median by 43.0 percentage points, which also exceeds the 20-point threshold, so the longer-term mitigant does not apply.
For Analysis
Ms. Andrews joined the board in March 2026, which is less than 24 months before the meeting date, so she is exempt from the TSR underperformance trigger under the policy's new-director exemption; she brings extensive oncology commercial and executive experience highly relevant to Geron's stage as a commercial-stage biotech company.
Mr. Chinoporos joined the board in March 2026, which is less than 24 months before the meeting date, so he is exempt from the TSR underperformance trigger under the policy's new-director exemption; he brings relevant biopharmaceutical business development and corporate strategy experience.
Of the three Class III nominees, two (Andrews and Chinoporos) joined in March 2026 and are exempt from the TSR trigger as new directors; one (Molineaux, director since 2012) triggers an AGAINST vote because Geron's stock underperformed the company's own peer group by 84.6 percentage points over three years and 43.0 percentage points over five years, both exceeding the applicable 20-point threshold for a stock with negative absolute three-year returns, leaving no basis for the five-year mitigant.
Say on Pay
✓ FORCEO
Harout Semerjian
Total Comp
$10,221,755
Prior Support
N/A
CEO Harout Semerjian received total compensation of approximately $10.2 million in 2025, his first year in the role (appointed August 2025), which is within a reasonable range for a CEO of a $1.1 billion commercial-stage biotech company given the competitive talent market for executives with hematology commercialization expertise; the pay program incorporates variable equity components tied to stock performance (options and RSUs), which aligns executive outcomes with shareholder outcomes, and the company maintains a clawback policy compliant with Nasdaq rules; no prior-year Say on Pay result is available to flag a pattern of shareholder concern, and no individual or aggregate compensation benchmark threshold is clearly breached given the transitional leadership context in 2025.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$2,613,294
Non-Audit Fees
$0
Ernst & Young charged $2,613,294 in audit fees for 2025 and zero in non-audit fees, making the non-audit fee ratio 0%, well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire under policy; at a market cap of $1.1 billion, a Big 4 firm is appropriate for the company's size and complexity.
Overall Assessment
The 2026 Geron annual meeting ballot presents four proposals; the clearest action item is an AGAINST vote on director nominee Susan M. Molineaux, whose 14-year tenure fully overlaps a period of severe stock underperformance — Geron's shares trailed its own disclosed peer group by 84.6 percentage points over three years and 43.0 percentage points over five years, both exceeding the policy trigger thresholds. The auditor ratification and Say on Pay proposals both pass policy screens and warrant FOR votes, while the equity plan expansion is outside the scope of this policy.
Compensation Peer Group
23 companies disclosed in 2026 proxy filing